DE69426725D1 - Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren - Google Patents

Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren

Info

Publication number
DE69426725D1
DE69426725D1 DE69426725T DE69426725T DE69426725D1 DE 69426725 D1 DE69426725 D1 DE 69426725D1 DE 69426725 T DE69426725 T DE 69426725T DE 69426725 T DE69426725 T DE 69426725T DE 69426725 D1 DE69426725 D1 DE 69426725D1
Authority
DE
Germany
Prior art keywords
hiv
peptides
nucleotide sequences
sequences
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69426725T
Other languages
English (en)
Other versions
DE69426725T2 (de
Inventor
Hermann Katinger
Thomas Muster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
POLIMUN SCIENT IMMUNBIOLOGISCH
Original Assignee
POLIMUN SCIENT IMMUNBIOLOGISCH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by POLIMUN SCIENT IMMUNBIOLOGISCH filed Critical POLIMUN SCIENT IMMUNBIOLOGISCH
Application granted granted Critical
Publication of DE69426725D1 publication Critical patent/DE69426725D1/de
Publication of DE69426725T2 publication Critical patent/DE69426725T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69426725T 1993-09-11 1994-09-12 Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren Expired - Fee Related DE69426725T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93114631 1993-09-11
PCT/EP1994/003039 WO1995007354A1 (en) 1993-09-11 1994-09-12 Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains

Publications (2)

Publication Number Publication Date
DE69426725D1 true DE69426725D1 (de) 2001-03-29
DE69426725T2 DE69426725T2 (de) 2001-09-06

Family

ID=8213253

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69426725T Expired - Fee Related DE69426725T2 (de) 1993-09-11 1994-09-12 Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren

Country Status (15)

Country Link
EP (1) EP0725825B1 (de)
JP (1) JPH09502348A (de)
CN (1) CN1135237A (de)
AT (1) ATE199260T1 (de)
AU (1) AU682893B2 (de)
BR (1) BR9407531A (de)
CA (1) CA2171544C (de)
CZ (1) CZ287808B6 (de)
DE (1) DE69426725T2 (de)
ES (1) ES2156902T3 (de)
HU (1) HU219507B (de)
PT (1) PT725825E (de)
RU (1) RU2181379C2 (de)
UA (1) UA43350C2 (de)
WO (1) WO1995007354A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033219A1 (en) * 1995-04-19 1996-10-24 Polymun Scientific Immunbiologische Forschung Gmbh Monoclonal antibodies against hiv-1 and vaccines made thereof
US6319890B1 (en) 1996-12-30 2001-11-20 Manfred P. Dierich Inhibition of binding of complement Factor H
CA2324348C (en) * 1998-03-23 2006-03-14 Trimeris, Inc. Methods and compositions for peptide synthesis
US6482928B1 (en) 1999-04-13 2002-11-19 Aventis Pasteur Limited And University Of Toronto Fab′-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5
CN1172717C (zh) * 2000-08-18 2004-10-27 清华大学 一种治疗艾滋病的药物及其制备方法
FR2851165A1 (fr) * 2003-02-19 2004-08-20 Aventis Pasteur Antigene derivant de l'helice c de la proteine gp41
CA2604683C (en) 2005-04-12 2019-04-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP1754715A1 (de) 2005-08-19 2007-02-21 Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut Impfstoff auf Basis virusneutralisierender Antikörper
WO2008127651A1 (en) 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
MX2011007745A (es) * 2009-02-06 2011-12-08 Mymetics Corp Division de gp41.
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69311764T2 (de) * 1992-05-14 1998-02-05 Polymun Scient Immunbio Forsch Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same

Also Published As

Publication number Publication date
UA43350C2 (uk) 2001-12-17
HU219507B (hu) 2001-04-28
CA2171544C (en) 2003-06-24
EP0725825B1 (de) 2001-02-21
EP0725825A1 (de) 1996-08-14
PT725825E (pt) 2001-08-30
JPH09502348A (ja) 1997-03-11
ES2156902T3 (es) 2001-08-01
CZ287808B6 (en) 2001-02-14
CA2171544A1 (en) 1995-03-16
CZ74196A3 (en) 1996-07-17
WO1995007354A1 (en) 1995-03-16
ATE199260T1 (de) 2001-03-15
AU7696594A (en) 1995-03-27
AU682893B2 (en) 1997-10-23
DE69426725T2 (de) 2001-09-06
HU9600587D0 (en) 1996-05-28
CN1135237A (zh) 1996-11-06
BR9407531A (pt) 1997-08-26
RU2181379C2 (ru) 2002-04-20
HUT76102A (en) 1997-06-30

Similar Documents

Publication Publication Date Title
DE3588251T2 (de) DNS-Fragmente des GAG-Gens von LAV
Kleny et al. Improved antigenicity of the HIV env protein by cleavage site removal
EP0339504A3 (de) Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen
CA2164818A1 (en) Tandem synthetic hiv-1 peptides
CA2392877A1 (en) Improvements in or relating to immune responses to hiv
DE69426725D1 (de) Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren
WO1991009872A3 (en) Hiv-1 env fragment fusion protein
DE69535035D1 (de) Präparate zur verabreichung von genetischem material
CA2143163A1 (en) Peptides derived from a retrovirus of the hiv group, and their use
JP2743164B2 (ja) Aidsの原因ウィルスの糖蛋白質をコードするウィルスベクター及び組換えdna、該ベクターにより感染された細胞培養物、並びに抗体
BRAND et al. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles
FR2700169B1 (fr) Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
Le Blanc et al. HTLV-1 structural proteins
CA2169603A1 (en) Retrovirus from the hiv group and its use
WO1993018055B1 (en) Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160
RU96108781A (ru) Пептиды, создающие нейтрализующие антитела к генетически дифергентным штаммам вич-1
CA2084386A1 (en) Hiv antigen
Lockey et al. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees
DE3789525T2 (de) Das F-Protein vom AIDS-Virus enthaltender Impfstoff.
Girard et al. Progress in the development of HIV vaccines
US6379679B1 (en) Multiple branch peptide construction
EP0469089B1 (de) Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
DE69008701T2 (de) Ein b-epitop des hüllglykoproteins eines retrovirus und ein t-epitop eines anderen proteins dieses retrovirus enthaltende zusammensetzung.
WO1998037089A8 (en) Matrix derived anti-hiv peptides and transdominant proteins
FR2607518A1 (fr) Vecteur viral et adn recombinant codant pour la proteine p25 du virus agent causal du s.i.d.a., culture cellulaire infectee, proteine obtenue, vaccin et anticorps obtenus

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee